Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shenzhen Transsion Holdings / Equity Capital Markets

Shenzhen Transsion Holdings Co., Ltd. manufactures and distributes communication devices. The Company produces mobile phones and phone accessories. Shenzhen Transsion Holdings markets products in China, Africa, and other countries and regions.

<ul>
<li>Transsion, a mobile phone maker focused on Africa and other emerging markets, raised HKD 2,968.0m (USD 378.2m) and will list on HKEX on Thursday, 15 Oct 2026.</li>
<li>In our previous notes, we looked at the company's fundamentals and the deal terms.</li>
<li>In this note, we provide an update for the IPO before its trading debut.</li>
</ul>


Transsion, a mobile phone maker focused on Africa and other emerging markets, raised HKD 2,968.0m (USD 378.2m) and will list on HKEX on Thursday, 15 Oct 2026.
In our previous notes, we looked at the company's fundamentals and the deal terms.
In this note, we provide an update for the IPO before its trading debut.


Smartkarma AI Synthetic Expert Call Transcripts, Smartkarma

αSK SmartScripts

Smartkarma AI Synthetic Expert Call Transcripts

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Z Fin Limited is a technology-driven enterprise focused on financial technology (FinTech) investment and management, having rebranded from a property-focused conglomerate. It invests in areas such as Artificial Intelligence, Web3 technologies, stablecoin regulatory regimes, and tokenization of Real-World Assets, while also providing financing and asset management services. The company was established in 1992 and is headquartered in Hong Kong.

<ul><li><strong style="font-weight:600;color:#1e293b;">The proposed HK$6.60 privatization offer severely undervalues Z Fin's core operations, effectively assigning a zero to negative implied valuation to its onshore P&amp;C underwriting business once the market value of its ZA Global stake and digital banking assets (ZA Bank) are backed out.</strong></li><li><strong style="font-weight:600;color:#1e293b;">Regulatory clearance across the NFRA and the HKEX presents significant structural hurdles; blocking the Scheme of Arrangement requires only a 10% vote from independent H-shareholders, making the offer highly vulnerable to activist or institutional arbitrageurs.</strong></li><li><strong style="font-weight:600;color:#1e293b;">Capital allocation history under Chairman Yaping Ou and the executive team reveals recurring alignment issues with minority H-shareholders, including non-core real estate purchases and equity dilution at steep discounts, which weakens board credibility heading into transaction votes.</strong></li></ul><div style="color: #475569; background: #eee; border-radius: 16px; padding: 14px; margin: 14px 0; font-size: 12px; line-height: 16px;"><p style="color: #333; margin-bottom: 4px; font-style: italic; font-size: 12px; line-height: 16px;">Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.</p></div>

The proposed HK$6.60 privatization offer severely undervalues Z Fin's core operations, effectively assigning a zero to negative implied valuation to its onshore P&amp;C underwriting business once the market value of its ZA Global stake and digital banking assets (ZA Bank) are backed out.Regulatory clearance across the NFRA and the HKEX presents significant structural hurdles; blocking the Scheme of Arrangement requires only a 10% vote from independent H-shareholders, making the offer highly vulnerable to activist or institutional arbitrageurs.Capital allocation history under Chairman Yaping Ou and the executive team reveals recurring alignment issues with minority H-shareholders, including non-core real estate purchases and equity dilution at steep discounts, which weakens board credibility heading into transaction votes.Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.

Z Fin (1168 HK): Synthetic Expert Call Transcript (14 Oct 2026)

Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.

<ul><li><strong style="font-weight:600;color:#1e293b;">Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the clinical superiority of bispecific antibody mechanisms over monotherapies, but shifting the global standard of care requires multi-regional Phase III validation across broader Western demographics.</strong></li><li><strong style="font-weight:600;color:#1e293b;">Akeso’s domestic growth remains robust with H1 2026 product sales reaching RMB 1,803.2 million, though NRDL price reductions have normalized gross margins to 79%; international enterprise value hinges on out-licensed royalty monetization and regulatory success, including Summit’s November 14, 2026 PDUFA decision.</strong></li><li><strong style="font-weight:600;color:#1e293b;">The HK$1.94 billion ($249 million) equity placement on October 13, 2026 at HK$97.76 per share reflects a proactive capital strategy to fully fund global registrational trials like COMPASSION-37 independently rather than relying solely on Western partners.</strong></li></ul><div style="color: #475569; background: #eee; border-radius: 16px; padding: 14px; margin: 14px 0; font-size: 12px; line-height: 16px;"><p style="color: #333; margin-bottom: 4px; font-style: italic; font-size: 12px; line-height: 16px;">Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.</p></div>

Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the clinical superiority of bispecific antibody mechanisms over monotherapies, but shifting the global standard of care requires multi-regional Phase III validation across broader Western demographics.Akeso’s domestic growth remains robust with H1 2026 product sales reaching RMB 1,803.2 million, though NRDL price reductions have normalized gross margins to 79%; international enterprise value hinges on out-licensed royalty monetization and regulatory success, including Summit’s November 14, 2026 PDUFA decision.The HK$1.94 billion ($249 million) equity placement on October 13, 2026 at HK$97.76 per share reflects a proactive capital strategy to fully fund global registrational trials like COMPASSION-37 independently rather than relying solely on Western partners.Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.

Akeso (9926 HK): Synthetic Expert Call Transcript (14 Oct 2026)

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

Beijing Wantai Biological Phar / Index Rebalance

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. manufactures medical products. The Company produces enzyme linked immunodiagnostic reagents, colloidal gold rapid diagnostic reagents, vaccines, biochemical reagents, and other products. Beijing Wantai Biological Pharmacy Enterprise also produces diagnostic equipment.

Beijing Wantai Biological Phar (603392 CH)

<ul>
<li>CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.</li>
<li>We expect five ADDs/DELs for the CSI Medical Service index during the upcoming index rebal  event based on the latest available data.</li>
<li>Nearly 95% of the reference period is now complete. We currently estimate one-way flow to be US$301mn.</li>
</ul>


CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.
We expect five ADDs/DELs for the CSI Medical Service index during the upcoming index rebal  event based on the latest available data.
Nearly 95% of the reference period is now complete. We currently estimate one-way flow to be US$301mn.


Quiddity Leaderboard CSI Medical Dec26: Expectations Have Changed; US$301mn One-Way

DapuStor Corporation designs and manufactures computer storage products. The Company produces solid-state drives (SSD), data storage processor chips, and edge computing-related products. DapuStor provides products for servers, telecom operators, and data centers.

<ul>
<li>ChiNext and ChiNext 50, respectively, represent the top 100 and top 50 A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.</li>
<li>We expect 7 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.</li>
<li>With approximately 91% of the review period complete, the rankings have largely stabilized.</li>
</ul>


ChiNext and ChiNext 50, respectively, represent the top 100 and top 50 A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.
We expect 7 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.
With approximately 91% of the review period complete, the rankings have largely stabilized.


Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Expected ADDs Sharply Down Vs Expected DELs